BioDelivery Sciences International Inc. (NASDAQ:BDSI) rose 2.9% on Tuesday . The company traded as high as $2.55 and last traded at $2.46, with a volume of 559,026 shares changing hands. The stock had previously closed at $2.39.

BDSI has been the topic of a number of research analyst reports. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a research note on Thursday, May 12th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $4.00 target price (down from $6.00) on shares of BioDelivery Sciences International in a research report on Thursday, May 12th. Cantor Fitzgerald downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and cut their target price for the stock from $9.00 to $5.00 in a research report on Wednesday, May 11th. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Wednesday, July 27th. Finally, Janney Montgomery Scott reiterated a “hold” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research report on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. BioDelivery Sciences International has an average rating of “Hold” and an average target price of $8.25.

The stock’s market capitalization is $132.65 million. The stock has a 50-day moving average of $2.44 and a 200-day moving average of $2.99.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.31). The company had revenue of $5 million for the quarter, compared to the consensus estimate of $3.35 million. The company’s quarterly revenue was up 194.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.37) earnings per share. Equities research analysts forecast that BioDelivery Sciences International Inc. will post ($1.16) earnings per share for the current year.

A hedge fund recently raised its stake in BioDelivery Sciences International stock. Bank of Montreal Can increased its stake in BioDelivery Sciences International Inc. (NASDAQ:BDSI) by 3.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 829,056 shares of the specialty pharmaceutical company’s stock after buying an additional 28,838 shares during the period. Bank of Montreal Can owned approximately 1.57% of BioDelivery Sciences International worth $3,971,000 as of its most recent SEC filing.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.